Synopsis: Following the US FDA’s escalation of action against its key Lanreotide supplier from Form 483 observations in November 2025, to OAI classification in February 2026, and now a formal import alert in April 2026.
A pharmaceutical supply chain problem that Cipla first disclosed to investors in November 2025 has now reached its most severe regulatory state. The US Food and Drug Administration issued Import Alert 66-40 against the Rodopi, Greece facility of Pharmathen International placing the facility on the agency’s “red list” and authorising US customs to detain shipments without physical examination. Cipla shares came under pressure on April 24 in response.
With a market capitalisation of Rs. 1,04,002.01 crore, the shares of Cipla were trading at Rs. 1,287.40 per share, down 1.42 percent from its previous close of Rs. 1,305.9. The stock carries a P/E of 23.21.
The import alert is the third escalation in a six-month sequence. In November 2025, the US FDA issued nine observations after inspecting Pharmathen’s Rodopi facility under current Good Manufacturing Practice (cGMP) standards flagging concerns around microbiological controls, aseptic processing, data lapses, and repeat deficiencies in standard operating procedures. In February 2026, the FDA upgraded the inspection classification to Official Action Indicated (OAI), and Cipla’s shares fell approximately 2.4 percent on that day alone. The April 2026 import alert takes the situation further: under Import Alert 66-40, shipments from listed facilities can be detained at the border without inspection, and the facility must complete corrective action and pass a re-inspection before exports can resume.
For Cipla, this is not peripheral. Lanreotide injection is one of the company’s top three products in the US market, holding a 22 percent market share in its segment. Losing supply continuity for a product at that scale creates both a revenue gap and an opening for competing generics to absorb market share that may not fully return even after supply normalises.
Business Overview
Cipla Limited, incorporated in 1935 and headquartered in Mumbai, is the third-largest company in the Indian domestic prescription market and one of the fastest-growing generic players in North America. The company operates across India, the US, South Africa, and other international markets, with a product portfolio spanning respiratory, urology, oncology, cardio-metabolism, HIV/AIDS, and critical care.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on the decision based on this article. Please consult your investment advisor before investing.
